Slow Response to Vancomycin or Vancomycin plus Rifampin in Methicillin-resistant Staphylococcus aureus Endocarditis
The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine the median response time to therapy with vancomycin alone or with vancomycin plus rifampin in patients with methicillin-resistant Staphylococcus aureus (MRSA) endocarditis. DESIGN: Cohort analysis of a randomized study. SETTING: University medical center. PATIENTS: Forty-two consecutive patients with MRSA endocarditis were randomly assigned to receive either vancomycin (group I) or vancomycin plus rifampin (group II) for 28 days. MEASUREMENTS: Clinical signs and symptoms were recorded, and blood cultures were obtained daily to determine the duration of bacteremia. MAIN RESULTS: The median duration of bacteremia was 9 days (7 days for group I and 9 days for group II). The median duration of fever for all patients and for each treatment group was 7 days. Six patients failed therapy, including three patients who died 5, 6, and 9 days after therapy was started, respectively. The other three patients who failed therapy required valve surgery on days 2, 22, and 27, respectively. Although patients had sustained bacteremia, no unusual complications were seen in either treatment group, and most patients responded to continued antibiotic therapy. CONCLUSIONS: Slow clinical response is common among patients with MRSA endocarditis who are treated with vancomycin or vancomycin plus rifampin. Nevertheless, few complications appear to be related solely to this sustained bacteremia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, a prospective trial in patients with IE caused by MRSA failed to demonstrate that the addition of rifampin to vancomycin either enhanced survival or reduced the duration of bacteremia compared with treatment with vancomycin alone.163”
Citations
Cites
A Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users
Small, P. M., & Chambers, H. F. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.6.1227 · Cited by 399
KORZENIOWSKI, O., & SANDE, M. A. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-4-496 · Cited by 355
LEVINE, D. P., CUSHING, R. D., JUI, J., & BROWN, W. J. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-3-330 · Cited by 224
Self-citationLevine, D. P., Crane, L. R., & Zervos, M. J. (1986) · Clinical Infectious Diseases · doi:10.1093/clinids/8.3.374 · Cited by 223
Self-citationChambers, H. F., Miller, R. T., & Newman, M. D. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-8-619 · Cited by 214
Antibiotic Tolerance Among Clinical Isolates of Bacteria
Handwerger, S., & Tomasz, A. (1985) · Clinical Infectious Diseases · doi:10.1093/clinids/7.3.368 · Cited by 206
Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations
Rotschafer, J. C., Crossley, K., Zaske, D. E., Mead, K., Sawchuk, R. J., & Solem, L. D. (1982) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.22.3.391 · Cited by 185
Staphylococcus aureus endocarditis: clinical manifestations in addicts and nonaddicts.
Witchitz, S., Wolff, M., Fraisse, F., Jj, G., Rouveix, É., & Regnier, B. (1983) · PubMed · Cited by 169
Staphylococcus aureus Endocarditis: Combined Therapy With Vancomycin and Rifampin
Faville, R. J. (1978) · JAMA · doi:10.1001/jama.1978.03290180037019 · Cited by 158
Research works printed but not linked: 1
- 10.1001/jama.1976.03270150038029 · doi:10.1001/jama.1976.03270150038029
Cited by
Staphylococcus aureus Infections
Lowy, F. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390806 · Cited by 6,005
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Self-citationBaddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Cosgrove, S. E., Sakoulas, G., Perencevich, E. N., Schwaber, M. J., Karchmer, A. W., & Carmeli, Y. (2003) · Clinical Infectious Diseases · doi:10.1086/345476 · Cited by 1,964
Metadata
- Authors
- Levine, D. P., Fromm, B. S., & Reddy, B. R.
- Affiliations
- Wayne State University (US)
- Harper University Hospital (US)
- ORCID
- Levine, Donald P.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1991-11-01
- Volume
- 115
- Issue
- 9
- Pages
- 674-680
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1975150477
- Cited by
- 577
- References
- 21
- Citations by year
- 2025: 2 · 2024: 9 · 2023: 10 · 2022: 4 · 2021: 5 · 2020: 7 · 2019: 5 · 2018: 10 · 2017: 9 · 2016: 12 · 2015: 21 · 2014: 12 · 2013: 27 · 2012: 10
- FWCI
- 12.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Streptococcal Infections and Treatments
- Keywords
- MRSA endocarditis, methicillin-resistant Staphylococcus aureus, vancomycin, rifampicin, combination antibiotic therapy, treatment response time, fever duration, treatment failure, valve surgery
- MeSH terms
- Adult, Drug Therapy, Combination, Endocarditis, Bacterial, Female, Fever, Gentamicins, Humans, Male, Middle Aged, Prospective Studies, Rifampin, Staphylococcal Infections, Statistics as Topic, Time Factors, Vancomycin, Methicillin Resistance, Bacteremia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Slow Response to Vancomycin or Vancomycin plus Rifampin in Methicillin-resistant Staphylococcus aureus Endocarditis. https://app.cochat.ai/papers/10.7326/0003-4819-115-9-674
- The paper
- Levine, D. P., Fromm, B. S., & Reddy, B. R. (1991). Slow Response to Vancomycin or Vancomycin plus Rifampin in Methicillin-resistant Staphylococcus aureus Endocarditis. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-115-9-674
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.